| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryoelectron Microscopy | 20 | 2026 | 243 | 3.600 |
Why?
|
| Exercise | 19 | 2025 | 881 | 3.230 |
Why?
|
| Cancer Survivors | 9 | 2025 | 273 | 2.320 |
Why?
|
| Receptors, Opioid, mu | 4 | 2026 | 34 | 1.570 |
Why?
|
| Drug Discovery | 2 | 2022 | 177 | 1.290 |
Why?
|
| Weight Loss | 4 | 2023 | 535 | 1.250 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2023 | 290 | 1.130 |
Why?
|
| Receptors, Neurotensin | 2 | 2026 | 6 | 1.110 |
Why?
|
| Motivation | 4 | 2024 | 328 | 1.060 |
Why?
|
| Models, Molecular | 10 | 2026 | 1060 | 1.050 |
Why?
|
| Self Efficacy | 5 | 2021 | 209 | 1.000 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2026 | 7 | 0.960 |
Why?
|
| Hodgkin Disease | 3 | 2026 | 306 | 0.950 |
Why?
|
| Ions | 1 | 2025 | 25 | 0.910 |
Why?
|
| Water | 1 | 2025 | 185 | 0.840 |
Why?
|
| Ligands | 11 | 2025 | 480 | 0.830 |
Why?
|
| Overweight | 4 | 2022 | 381 | 0.820 |
Why?
|
| Molecular Dynamics Simulation | 3 | 2025 | 124 | 0.780 |
Why?
|
| Weight Reduction Programs | 2 | 2022 | 59 | 0.760 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 2597 | 0.720 |
Why?
|
| Social Media | 1 | 2024 | 120 | 0.720 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 5 | 2026 | 21 | 0.720 |
Why?
|
| Receptors, Somatostatin | 1 | 2022 | 55 | 0.710 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 108 | 0.680 |
Why?
|
| Mindfulness | 1 | 2021 | 33 | 0.660 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2021 | 45 | 0.640 |
Why?
|
| Text Messaging | 1 | 2020 | 41 | 0.640 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 364 | 0.610 |
Why?
|
| Mobile Applications | 1 | 2021 | 112 | 0.610 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2026 | 1265 | 0.590 |
Why?
|
| Proteins | 2 | 2025 | 1004 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 1325 | 0.580 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 336 | 0.580 |
Why?
|
| Neoplasms | 6 | 2025 | 2979 | 0.570 |
Why?
|
| Diet | 2 | 2023 | 1101 | 0.570 |
Why?
|
| Muscle Strength | 1 | 2018 | 77 | 0.520 |
Why?
|
| Urban Population | 2 | 2025 | 281 | 0.520 |
Why?
|
| Rural Population | 2 | 2025 | 270 | 0.500 |
Why?
|
| Analgesics, Opioid | 4 | 2026 | 484 | 0.480 |
Why?
|
| Guanosine Triphosphate | 2 | 2026 | 38 | 0.470 |
Why?
|
| Aging | 1 | 2023 | 1238 | 0.470 |
Why?
|
| Obesity | 5 | 2022 | 2397 | 0.460 |
Why?
|
| Health Behavior | 4 | 2020 | 386 | 0.460 |
Why?
|
| Humans | 50 | 2026 | 130066 | 0.450 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1589 | 0.430 |
Why?
|
| Signal Transduction | 10 | 2026 | 4644 | 0.420 |
Why?
|
| Middle Aged | 18 | 2026 | 28314 | 0.420 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 3 | 2024 | 32 | 0.410 |
Why?
|
| Schools | 4 | 2023 | 236 | 0.400 |
Why?
|
| Ipilimumab | 2 | 2026 | 64 | 0.390 |
Why?
|
| Aged | 13 | 2026 | 20820 | 0.390 |
Why?
|
| Protein Conformation | 3 | 2025 | 732 | 0.390 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 2024 | 11 | 0.380 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 3 | 2024 | 18 | 0.360 |
Why?
|
| Hallucinogens | 3 | 2022 | 67 | 0.360 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2022 | 11 | 0.350 |
Why?
|
| Quality of Life | 3 | 2025 | 2072 | 0.350 |
Why?
|
| Ecological Momentary Assessment | 2 | 2022 | 10 | 0.350 |
Why?
|
| Protein Binding | 6 | 2026 | 1649 | 0.350 |
Why?
|
| Feasibility Studies | 4 | 2025 | 820 | 0.340 |
Why?
|
| Fitness Trackers | 2 | 2021 | 15 | 0.320 |
Why?
|
| Female | 23 | 2026 | 70239 | 0.300 |
Why?
|
| Adult | 15 | 2026 | 31012 | 0.300 |
Why?
|
| Smartphone | 2 | 2025 | 45 | 0.280 |
Why?
|
| Health Promotion | 2 | 2024 | 416 | 0.280 |
Why?
|
| Protein Multimerization | 4 | 2021 | 148 | 0.270 |
Why?
|
| beta-Arrestins | 3 | 2022 | 30 | 0.250 |
Why?
|
| Amino Acid Motifs | 1 | 2026 | 189 | 0.230 |
Why?
|
| Lysergic Acid Diethylamide | 2 | 2022 | 13 | 0.230 |
Why?
|
| HEK293 Cells | 2 | 2025 | 800 | 0.230 |
Why?
|
| Occupational Therapy | 1 | 2025 | 37 | 0.220 |
Why?
|
| Deception | 1 | 2025 | 10 | 0.220 |
Why?
|
| Analgesics | 1 | 2026 | 119 | 0.220 |
Why?
|
| Data Accuracy | 1 | 2025 | 28 | 0.220 |
Why?
|
| Survivorship | 1 | 2024 | 45 | 0.210 |
Why?
|
| Leisure Activities | 1 | 2023 | 11 | 0.200 |
Why?
|
| Molecular Docking Simulation | 2 | 2025 | 147 | 0.200 |
Why?
|
| Mexico | 1 | 2023 | 190 | 0.190 |
Why?
|
| Endocannabinoids | 1 | 2023 | 28 | 0.190 |
Why?
|
| Morphinans | 1 | 2022 | 2 | 0.190 |
Why?
|
| Cooking | 1 | 2023 | 37 | 0.190 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2022 | 5 | 0.190 |
Why?
|
| Crystallization | 1 | 2022 | 83 | 0.190 |
Why?
|
| Fatigue | 1 | 2024 | 191 | 0.190 |
Why?
|
| Workplace | 2 | 2022 | 80 | 0.190 |
Why?
|
| Biological Assay | 1 | 2023 | 105 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 149 | 0.190 |
Why?
|
| Pyrrolidines | 1 | 2022 | 50 | 0.180 |
Why?
|
| Entropy | 1 | 2022 | 30 | 0.180 |
Why?
|
| Fentanyl | 1 | 2022 | 53 | 0.180 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2021 | 6 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 26 | 0.180 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2021 | 11 | 0.180 |
Why?
|
| Telemedicine | 2 | 2025 | 525 | 0.170 |
Why?
|
| Magnesium | 1 | 2022 | 114 | 0.170 |
Why?
|
| Drug Design | 1 | 2022 | 159 | 0.170 |
Why?
|
| Male | 16 | 2026 | 64378 | 0.170 |
Why?
|
| Oxytocin | 1 | 2022 | 68 | 0.170 |
Why?
|
| Survivors | 1 | 2024 | 345 | 0.170 |
Why?
|
| School Teachers | 1 | 2021 | 9 | 0.170 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2021 | 48 | 0.170 |
Why?
|
| Technology | 1 | 2021 | 68 | 0.170 |
Why?
|
| Receptors, GABA-B | 1 | 2020 | 11 | 0.160 |
Why?
|
| Lipids | 2 | 2024 | 559 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2020 | 15 | 0.160 |
Why?
|
| Quantum Theory | 1 | 2020 | 19 | 0.160 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 81 | 0.160 |
Why?
|
| beta-Arrestin 1 | 1 | 2020 | 4 | 0.160 |
Why?
|
| Calcium | 2 | 2024 | 1008 | 0.160 |
Why?
|
| Binding Sites | 4 | 2025 | 1134 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 319 | 0.150 |
Why?
|
| Teaching | 1 | 2021 | 196 | 0.150 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2019 | 1 | 0.150 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1264 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1481 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 122 | 0.150 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2019 | 11 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 126 | 0.150 |
Why?
|
| Affect | 1 | 2020 | 160 | 0.150 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2019 | 25 | 0.140 |
Why?
|
| Peptides | 4 | 2023 | 704 | 0.140 |
Why?
|
| Students | 1 | 2021 | 247 | 0.140 |
Why?
|
| Models, Psychological | 1 | 2019 | 138 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 477 | 0.140 |
Why?
|
| Cholesterol | 1 | 2021 | 537 | 0.140 |
Why?
|
| Health Surveys | 1 | 2019 | 258 | 0.140 |
Why?
|
| Animals | 9 | 2026 | 33641 | 0.140 |
Why?
|
| Cognition | 1 | 2023 | 818 | 0.140 |
Why?
|
| Substrate Specificity | 3 | 2024 | 285 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 4035 | 0.130 |
Why?
|
| Pandemics | 2 | 2021 | 1113 | 0.130 |
Why?
|
| Glucose | 1 | 2021 | 851 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 563 | 0.120 |
Why?
|
| Linear Models | 1 | 2018 | 685 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 348 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 439 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2018 | 271 | 0.110 |
Why?
|
| Adolescent | 3 | 2026 | 20797 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 1455 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 688 | 0.110 |
Why?
|
| Communication | 1 | 2019 | 540 | 0.110 |
Why?
|
| Cell Membrane | 3 | 2022 | 449 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1241 | 0.110 |
Why?
|
| Collagen Type VI | 1 | 2014 | 7 | 0.110 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2014 | 9 | 0.110 |
Why?
|
| Hemocyanins | 1 | 2014 | 23 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 67 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2014 | 31 | 0.100 |
Why?
|
| Sleep | 3 | 2022 | 374 | 0.100 |
Why?
|
| Young Adult | 2 | 2026 | 9981 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2023 | 5036 | 0.100 |
Why?
|
| Physical Education and Training | 2 | 2023 | 14 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 188 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2023 | 308 | 0.090 |
Why?
|
| Allosteric Regulation | 2 | 2024 | 58 | 0.090 |
Why?
|
| Nanostructures | 2 | 2024 | 66 | 0.090 |
Why?
|
| GTP-Binding Proteins | 2 | 2022 | 156 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 1273 | 0.090 |
Why?
|
| Pain | 2 | 2026 | 430 | 0.080 |
Why?
|
| Serotonin | 2 | 2022 | 209 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 355 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6765 | 0.080 |
Why?
|
| Protein Stability | 2 | 2020 | 164 | 0.070 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2016 | 683 | 0.070 |
Why?
|
| Protein Domains | 2 | 2020 | 251 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3782 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2026 | 39 | 0.060 |
Why?
|
| Mice | 4 | 2026 | 18144 | 0.060 |
Why?
|
| Nucleus Accumbens | 1 | 2026 | 55 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2026 | 155 | 0.050 |
Why?
|
| Oklahoma | 1 | 2024 | 9 | 0.050 |
Why?
|
| Dopamine | 1 | 2026 | 244 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1545 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2026 | 300 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2004 | 124 | 0.050 |
Why?
|
| Polyamines | 1 | 2024 | 36 | 0.050 |
Why?
|
| Tryptophan | 1 | 2024 | 83 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2026 | 1109 | 0.050 |
Why?
|
| Arrestins | 1 | 2022 | 24 | 0.050 |
Why?
|
| Nociception | 1 | 2022 | 13 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 163 | 0.050 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Chemotactic Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2022 | 37 | 0.050 |
Why?
|
| Cell Line | 2 | 2020 | 2551 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2022 | 47 | 0.050 |
Why?
|
| Receptors, Vasopressin | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cations | 1 | 2022 | 38 | 0.050 |
Why?
|
| Receptors, Oxytocin | 1 | 2022 | 20 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2021 | 11 | 0.040 |
Why?
|
| Receptors, Peptide | 1 | 2022 | 54 | 0.040 |
Why?
|
| United States | 3 | 2025 | 11893 | 0.040 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2021 | 38 | 0.040 |
Why?
|
| Saccharomycetales | 1 | 2021 | 36 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 109 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2025 | 1439 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2022 | 130 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2023 | 322 | 0.040 |
Why?
|
| School Health Services | 1 | 2022 | 103 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1316 | 0.040 |
Why?
|
| Ion Channel Gating | 1 | 2021 | 119 | 0.040 |
Why?
|
| Methiothepin | 1 | 2020 | 1 | 0.040 |
Why?
|
| Spodoptera | 1 | 2020 | 28 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2020 | 17 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12818 | 0.040 |
Why?
|
| GABA-B Receptor Antagonists | 1 | 2020 | 1 | 0.040 |
Why?
|
| Recurrence | 2 | 2020 | 1475 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 280 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2020 | 78 | 0.040 |
Why?
|
| Receptors, Glutamate | 1 | 2020 | 17 | 0.040 |
Why?
|
| Social Isolation | 1 | 2020 | 49 | 0.040 |
Why?
|
| Neutrophils | 1 | 2022 | 362 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 61 | 0.040 |
Why?
|
| Rats | 1 | 2026 | 3371 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2020 | 92 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 99 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2020 | 157 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 552 | 0.040 |
Why?
|
| Sf9 Cells | 1 | 2019 | 10 | 0.040 |
Why?
|
| Receptors, Cannabinoid | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2019 | 7 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 36 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 140 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 552 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 235 | 0.040 |
Why?
|
| Cannabinoids | 1 | 2019 | 32 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 231 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 327 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 668 | 0.030 |
Why?
|
| Cysteine | 1 | 2019 | 137 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2020 | 716 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 2020 | 226 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2022 | 532 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 271 | 0.030 |
Why?
|
| Feedback | 1 | 2018 | 143 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1166 | 0.030 |
Why?
|
| Intention | 1 | 2017 | 102 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 668 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2022 | 981 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2026 | 4688 | 0.030 |
Why?
|
| Emotions | 1 | 2019 | 348 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 239 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 1570 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1480 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2108 | 0.030 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1584 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2192 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 712 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 237 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2017 | 709 | 0.020 |
Why?
|
| Vincristine | 1 | 2014 | 188 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 232 | 0.020 |
Why?
|
| Monocytes | 1 | 2014 | 335 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 3655 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 425 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 1057 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1614 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1406 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 905 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7389 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2014 | 758 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 1160 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 6068 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 135 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 237 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 902 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1481 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 13266 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 17537 | 0.010 |
Why?
|
| Child | 1 | 2016 | 26169 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6165 | 0.010 |
Why?
|